Chemed CHE Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost at other companies
Other financials
Where this comes from
Reported directly by Chemed in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost.
The official record: Chemed’s 10-K, filed February 27, 2026, on SEC EDGAR. View the filing →
Ask your AI about Chemed's deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Chemed's deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost?
- Chemed (CHE) reported deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost of $13.02M in Q4 2025.
- How has Chemed's deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost changed year-over-year?
- Chemed's deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost increased by 15.9% year-over-year, from $11.23M to $13.02M.
- What is the long-term trend for Chemed's deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost?
- Over 5 years (2020 to 2025), Chemed's deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost has grown at a 26.3% compound annual growth rate (CAGR), from $4.05M to $13.02M.